Risks

High net debt to EBITDA and sub-1x interest coverage leave ZIMV more exposed than peers if reimbursement or demand conditions soften, constraining financial flexibility.

A very long cash conversion cycle driven by elevated inventory and receivables days can pressure working capital versus faster-turning medtech peers, limiting cash generation.

If procedure volumes or capital equipment spending slow, ZIMV’s leverage profile can amplify downside more than lower-debt peers, especially in a tighter funding environment.

The company’s liquidity ratios are adequate, but they provide less protection than stronger-balance-sheet peers if operating volatility or refinancing costs rise.

Opportunities

Current and quick ratios above 2.0 and 1.6, respectively, give ZIMV more near-term liquidity headroom than many leveraged medtech peers, supporting execution stability.

If demand for elective procedures and hospital capital spending normalizes, ZIMV can convert its liquidity buffer into faster growth than peers with tighter working capital.

Improving inventory and receivables management could release cash from the balance sheet, creating a clearer path to deleveraging versus slower-turning peers.

A more manageable near-term liquidity position may help ZIMV sustain commercial investment through cyclical softness better than peers with weaker cash coverage.

Overall Score

ZIMV’s forward positioning is balanced by meaningful leverage and working-capital pressure, while solid liquidity and potential demand normalization provide some peer-relative upside.